Juliana Cassataro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5804586/publications.pdf

Version: 2024-02-01

52 papers	2,210 citations	186265 28 h-index	46 g-index
53	53	53	1397 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice. Frontiers in Immunology, 2022, 13, 844837.	4.8	13
2	Stability Studies of the Vaccine Adjuvant U-Omp19. Journal of Pharmaceutical Sciences, 2021, 110, 707-718.	3.3	6
3	The Trypanosoma cruzi TcTASV-C protein subfamily administrated with U-Omp19 promotes a protective response against a lethal challenge in mice. Vaccine, 2020, 38, 7645-7653.	3.8	6
4	Sublingual Omp16â€driven redirection of the allergic intestinal response in a preâ€clinical model of food allergy. Clinical and Experimental Allergy, 2020, 50, 954-963.	2.9	4
5	U-Omp19 from Brucella abortus increases dmLT immunogenicity and improves protection against Escherichia coli heat-labile toxin (LT) oral challenge. Vaccine, 2020, 38, 5027-5035.	3.8	2
6	Omp25â€dependent engagement of SLAMF1 by <scp><i>Brucella abortus</i></scp> in dendritic cells limits acute inflammation and favours bacterial persistence in vivo. Cellular Microbiology, 2020, 22, e13164.	2.1	14
7	Omp19 Enables Brucella abortus to Evade the Antimicrobial Activity From Host's Proteolytic Defense System. Frontiers in Immunology, 2019, 10, 1436.	4.8	15
8	Oral co-administration of a bacterial protease inhibitor in the vaccine formulation increases antigen delivery at the intestinal epithelial barrier. Journal of Controlled Release, 2019, 293, 158-171.	9.9	13
9	U-Omp19 from Brucella abortus Is a Useful Adjuvant for Vaccine Formulations against Salmonella Infection in Mice. Frontiers in Immunology, 2017, 8, 171.	4.8	30
10	A <i>Brucella</i> spp. Protease Inhibitor Limits Antigen Lysosomal Proteolysis, Increases Cross-Presentation, and Enhances CD8+ T Cell Responses. Journal of Immunology, 2016, 196, 4014-4029.	0.8	32
11	Brucella abortus Omp19 recombinant protein subcutaneously co-delivered with an antigen enhances antigen-specific T helper 1 memory responses and induces protection against parasite challenge. Vaccine, 2016, 34, 430-437.	3.8	15
12	A bacterial protease inhibitor protects antigens delivered in oral vaccines from digestion while triggering specific mucosal immune responses. Journal of Controlled Release, 2015, 220, 18-28.	9.9	28
13	Brucella Cyclic \hat{l}^2 -1,2-Glucan Plays a Critical Role in the Induction of Splenomegaly in Mice. PLoS ONE, 2014, 9, e101279.	2.5	27
14	Oral delivery of Brucella spp. recombinant protein U-Omp16 abrogates the IgE-mediated milk allergy. Human Vaccines and Immunotherapeutics, 2014, 10, 2015-2023.	3.3	9
15	Evaluation of the Efficacy of Outer Membrane Protein 31 Vaccine Formulations for Protection against Brucella canis in BALB/c Mice. Vaccine Journal, 2014, 21, 1689-1694.	3.1	25
16	The vaccine candidate BLSOmp31 protects mice against Brucella canis infection. Vaccine, 2013, 31, 6129-6135.	3.8	34
17	Brucella abortus induces TNF-α-dependent astroglial MMP-9 secretion through mitogen-activated protein kinases. Journal of Neuroinflammation, 2013, 10, 47.	7.2	30
18	<i>Brucella abortus</i> induces intracellular retention of MHC-I molecules in human macrophages down-modulating cytotoxic CD8 ⁺ T cell responses. Cellular Microbiology, 2013, 15, 487-502.	2.1	38

#	Article	IF	Citations
19	Toll-Like Receptor 6 Plays an Important Role in Host Innate Resistance to Brucella abortus Infection in Mice. Infection and Immunity, 2013, 81, 1654-1662.		45
20	Unlipidated Outer Membrane Protein Omp16 (U-Omp16) from Brucella spp. as Nasal Adjuvant Induces a Th1 Immune Response and Modulates the Th2 Allergic Response to Cow's Milk Proteins. PLoS ONE, 2013, 8, e69438.	2.5	19
21	Targeting Stat3 Induces Senescence in Tumor Cells and Elicits Prophylactic and Therapeutic Immune Responses against Breast Cancer Growth Mediated by NK Cells and CD4+ T Cells. Journal of Immunology, 2012, 189, 1162-1172.	0.8	46
22	Brucella abortus induces apoptosis of human T lymphocytes. Microbes and Infection, 2012, 14, 639-650.	1.9	31
23	Confronting the barriers to develop novel vaccines against brucellosis. Expert Review of Vaccines, 2011, 10, 1291-1305.	4.4	48
24	An Oral Vaccine Based on U-Omp19 Induces Protection against B. abortus Mucosal Challenge by Inducing an Adaptive IL-17 Immune Response in Mice. PLoS ONE, 2011, 6, e16203.	2.5	94
25	Brucella abortus inhibits IFN- \hat{I}^3 -induced Fc \hat{I}^3 RI expression and Fc \hat{I}^3 RI-restricted phagocytosis via toll-like receptor 2 on human monocytes/macrophages. Microbes and Infection, 2011, 13, 239-250.	1.9	19
26	The Protein Moiety of <i>Brucella abortus</i> Outer Membrane Protein 16 Is a New Bacterial Pathogen-Associated Molecular Pattern That Activates Dendritic Cells In Vivo, Induces a Th1 Immune Response, and Is a Promising Self-Adjuvanting Vaccine against Systemic and Oral Acquired Brucellosis. Journal of Immunology, 2010, 184, 5200-5212.	0.8	63
27	Brucella abortus Induces the Secretion of Proinflammatory Mediators from Glial Cells Leading to Astrocyte Apoptosis. American Journal of Pathology, 2010, 176, 1323-1338.	3.8	59
28	Immunization with Recombinant Brucella Species Outer Membrane Protein Omp16 or Omp19 in Adjuvant Induces Specific CD4+ and CD8+ T Cells as Well as Systemic and Oral Protection against Brucella abortus Infection. Infection and Immunity, 2009, 77, 436-445.	2.2	126
29	Brucella abortus activates human neutrophils. Microbes and Infection, 2009, 11, 689-697.	1.9	35
30	The polymeric antigen BLSOmp31 confers protection against Brucella ovis infection in rams. Vaccine, 2009, 27, 6704-6711.	3.8	41
31	Immunization with Recombinant <i>Brucella</i> Species Outer Membrane Protein Omp16 or Omp19 in Adjuvant Induces Specific CD4 ⁺ and CD8 ⁺ T Cells as Well as Systemic and Oral Protection against <i>Brucella abortus</i> Infection. Infection and Immunity, 2009, 77, 1719-1719.	2.2	9
32	Brucella lipoproteins mimic dendritic cell maturation induced by Brucella abortus. Microbes and Infection, 2008, 10, 1346-1354.	1.9	54
33	<i>Brucella abortus</i> Inhibits Major Histocompatibility Complex Class II Expression and Antigen Processing through Interleukin-6 Secretion via Toll-Like Receptor 2. Infection and Immunity, 2008, 76, 250-262.	2.2	73
34	A Bile Salt Hydrolase of Brucella abortus Contributes to the Establishment of a Successful Infection through the Oral Route in Mice. Infection and Immunity, 2007, 75, 299-305.	2.2	66
35	Improved Immunogenicity of a Vaccination Regimen Combining a DNA Vaccine Encoding Brucella melitensis Outer Membrane Protein 31 (Omp31) and Recombinant Omp31 Boosting. Vaccine Journal, 2007, 14, 869-874.	3.1	43
36	A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Vaccine, 2007, 25, 4437-4446.	3.8	61

#	Article	IF	CITATIONS
37	A DNA vaccine coding for the chimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. Vaccine, 2007, 25, 5958-5967.	3.8	38
38	Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice. Vaccine, 2007, 25, 6721-6729.	3.8	92
39	Brucella outer membrane protein Omp31 is a haemin-binding protein. Microbes and Infection, 2006, 8, 1203-1208.	1.9	19
40	Immunization with Murine Breast Cancer Cells Treated with Antisense Oligodeoxynucleotides to Type I Insulin-Like Growth Factor Receptor Induced an Antitumoral Effect Mediated by a CD8+ Response Involving Fas/Fas Ligand Cytotoxic Pathway. Journal of Immunology, 2006, 176, 3426-3437.	0.8	25
41	A DNA Vaccine Coding for the Brucella Outer Membrane Protein 31 Confers Protection against B. melitensis and B. ovis Infection by Eliciting a Specific Cytotoxic Response. Infection and Immunity, 2005, 73, 6537-6546.	2.2	107
42	Vaccination with the Recombinant Brucella Outer Membrane Protein 31 or a Derived 27-Amino-Acid Synthetic Peptide Elicits a CD4+ T Helper 1 Response That Protects against Brucella melitensis Infection. Infection and Immunity, 2005, 73, 8079-8088.	2.2	107
43	Antibody Reactivity to Omp31 from Brucella melitensis in Human and Animal Infections by Smooth and Rough Brucellae. Vaccine Journal, 2004, 11, 111-114.	3.1	52
44	Lipoproteins, Not Lipopolysaccharide, Are the Key Mediators of the Proinflammatory Response Elicited by Heat-Killed <i>Brucella abortus</i> . Journal of Immunology, 2004, 173, 4635-4642.	0.8	166
45	Immunogenicity of recombinant Omp31 from Brucella melitensis in rams and serum bactericidal activity against B. ovis. Veterinary Microbiology, 2004, 102, 203-213.	1.9	28
46	The recombinant Omp31 from Brucella melitensis alone or associated with rough lipopolysaccharide induces protection against Brucella ovis infection in BALB/c mice. Microbes and Infection, 2003, 5, 85-93.	1.9	55
47	Antibodies to the CP24 protein of Brucella melitensis lack diagnostic usefulness in ovine brucellosis. Veterinary Microbiology, 2003, 93, 101-107.	1.9	2
48	Brucella Lumazine Synthase Elicits a Mixed Th1-Th2 Immune Response and Reduces Infection in Mice Challenged with Brucella abortus 544 Independently of the Adjuvant Formulation Used. Infection and Immunity, 2003, 71, 5750-5755.	2.2	93
49	Diagnostic Usefulness of Antibodies against Ribosome Recycling Factor from Brucella melitensis in Human or Canine Brucellosis. Vaccine Journal, 2002, 9, 366-369.	3.1	7
50	A DNA Vaccine Encoding Lumazine Synthase from Brucella abortus Induces Protective Immunity in BALB/c Mice. Infection and Immunity, 2002, 70, 2507-2511.	2.2	95
51	Immunogenicity of the Brucella melitensis recombinant ribosome recycling factor-homologous protein and its cDNA. Vaccine, 2002, 20, 1660-1669.	3.8	20
52	Single-shot plasmid DNA intrasplenic immunization for the production of monoclonal antibodies. Journal of Immunological Methods, 2000, 244, 1-7.	1.4	30